期刊
PHARMACOGENOMICS JOURNAL
卷 10, 期 1, 页码 1-11出版社
SPRINGERNATURE
DOI: 10.1038/tpj.2009.54
关键词
cholesterol; myopathy; polymorphism; SLCO1B1; statin; transporter
资金
- Heart Research UK
- Jean Shanks Foundation
- Leeds Teaching Hospitals Charitable Foundation
Statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) are well established in the treatment of hypercholesterolaemia and the prevention of coronary artery disease. Despite this, there is wide inter-individual variability in response to statin therapy, in terms of both lipid-lowering and adverse drug reactions. The major site of statin action is within hepatocytes and recent interest has focussed on genetic variation in hepatic influx and efflux transporters for their potential to explain these differences. In this review we explore current literature regarding the pharmacokinetic and pharmacodynamic influence of the common c.388A>G and c.521T>C single-nucleotide polymorphisms (SNPs) within the solute carrier organic anion transporter 1B1 (SLCO1B1) gene, encoding the organic anion transporter polypeptide 1B1 (OATP1B1) influx transporter. We discuss their potential to predict the efficacy of statin therapy and the likelihood that patients will experience adverse effects. The Pharmacogenomics Journal (2010) 10, 1-11; doi: 10.1038/tpj.2009.54; published online 3 November 2009
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据